Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
Sol-Gel Technologies Ltd. (SLGL)
Last sol-gel technologies ltd. earnings: 11/13 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/markets/ipos/company/solgel-technologies-ltd-1031585-84610
Company Research
Source: GlobeNewswire
- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates - Sol-Gel’s cash runway expected to extend through at least Q4 2023 - Sol-Gel’s focus remains on supporting Galderma to launch TWYNEO®, and EPSOLAY®, subject to its FDA approval, along with advancing its innovative pipeline of assets NESS ZIONA, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), (“Sol-Gel”), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced a new agreement with Padagis (formerly a division of Perrigo Company plc) (the “Agreement”), which will replace prior collaborative agreements for the development and commercialization of certain generic drugs
Show less
Read more
Impact Snapshot
Event Time:
SLGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLGL alerts
High impacting Sol-Gel Technologies Ltd. news events
Weekly update
A roundup of the hottest topics
SLGL
News
- Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream [Yahoo! Finance]Yahoo! Finance
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamGlobeNewswire
- Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]Yahoo! Finance
- Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M [Seeking Alpha]Seeking Alpha
- Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsGlobeNewswire
SLGL
Earnings
- 11/9/23 - Beat
SLGL
Sec Filings
- 4/8/24 - Form SC
- 4/4/24 - Form 424B3
- 4/2/24 - Form EFFECT
- SLGL's page on the SEC website